On December 1, 2021 Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, reported that it has been granted United States Patent No. 11,185,523, "Use of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for Treatment of Cancer," by the United States Patent and Trademark Office (Press release, Diffusion Pharmaceuticals, DEC 1, 2021, View Source [SID1234596325]). This patent includes new claims related to methods of treating cancerous tumors by administering the Company’s lead product candidate, trans sodium crocetinate ("TSC"), in combination with radiation therapy and chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe the issuance of this patent represents another important step in our development of TSC and provides us with additional intellectual property protection to support the design and execution of our recently announced clinical program to support the use of intravenously administered TSC as a treatment for hypoxic solid tumors," said Robert J. Cobuzzi, Jr., Ph.D., President and Chief Executive Office of Diffusion.